P53 and the Carcinoma of the Breast: A Review

P53 and the Carcinoma of the Breast

Keywords: p53, oncogenesis, tumor suppressor gene, carcinoma breast, guardian of genome, apoptosis

Abstract

TP53 is a gene and p53 is its product protein. Since its discovery many studies have looked into its function and its role in cancer. It is not   only involved in the induction of apoptosis but is also, a key player, in cell cycle regulation, development, differentiation, gene amplification, DNA recombination, chromosomal segregation and cellular senescence and so, it is called “the guardian of genome”. The human TP53 gene spans 20kb on chromosome band 17p13.1. The biological functions of p53 are apoptosis, senescence and cell migration. The evolution of a normal cell towards a cancerous one is a complex process. Tumorogenesis is considered to endow, the evolving tumor with, self-sufficiency of growth signals, insensitivity to antigrowth signals, evasion from programmed cell death, unlimited replicative potentials and finally the ability to invade and metastasize. TP53 may be considered as the “ultimate tumor suppressor gene”. Its oncogenic activity is attributed to loss of function, dominant negative (DN) oncogenic properties and activities of mutant p53. In breast cancer its oncogenic function is due to p53 mutation, changes in- upstream regulatory pathways, in p53 transcriptional target genes, in p53 co-activators, and/or involvement of other family members of p53 family like p63 and p73. The p53 mutation is present in only in about 20% of breast cancers, but when present, they entail the worst prognosis. This interesting paper is a review and discussion about role of p53 in carcinoma breast.

Downloads

Download data is not yet available.

References

Agrawal SN, Dhruv K, S M. P53: The Guardian of genome, Apoptosis, and its role in carcinogenesis. Eur J Biomed Pharmaceut Sci. 2017;4(2):161–66.

Oren M, Rotter V. Introduction: p53 – the first twenty years. Cellular Molecular Life Sci CMLS. 1999;55(1):9–11. Available from: https://dx.doi.org/10.1007/s000180050265.

Lane DP. p53, guardian of the genome. Nature. 1992;358(6381):15–16. Available from: https://dx.doi.org/10.1038/358015a0.

Narayana AS. P53: Its role in carcinogenesis and also a novel target for anti-cancer therapy. IOSR-J Dent Med Sci. 2016;15(9):28–34.

Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nature Genetics. 2004;36(2):147–150. Available from: https://dx.doi.org/10.1038/ng1293.

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–310. Available from:

https://dx.doi.org/10.1038/35042675.

Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics. Br J Cancer. 1972;26(4):239–257. Available from: https://dx.doi.org/10.1038/bjc.1972.33.

Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, et al. Classification of cell death: recom- mendations of the Nomenclature Committee on Cell Death. Cell Death Different. 2005;12(S2):1463–1467. Available from: https://dx.doi.org/10.1038/sj.cdd.4401724.

Manjo G, Joris I. Apoptosis, oncosis and necrosis. An overview of cell death. Am J Pathol. 1995;146:3–15.

Kumar V, Abbas AK, Aster FN, Robins JC. Pathologic basis of disease. Philadelphia: W.B. Saunders Elsevier; 2010.

Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nature Rev Molecular Cell Biol. 2007;8(9):729–740. Available from: https://dx.doi.org/10.1038/nrm2233.

Gadea G. Regulation of Cdc42-mediated morphological effects: a novel function for p53. The EMBO Journal. 2002;21(10):2373–2382. Available from: https://dx.doi.org/10.1093/emboj/21.10.2373.

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57–70. Available from: https://dx.doi.org/10.1016/s0092-8674(00)81683-9.

Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999;274:36031–36035.

Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60:6788–93.

Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature. 1986;319(6056):783–784. Available from: https://dx.doi.org/10.1038/319783a0.

Milner J, Medcalf EA, Cook AC. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Molecular Cellular Biol. 1991;11(1):12–19. Available from: https://dx.doi.org/10.1128/mcb.11.1.12.

Milner J, Medcalf EA. Co translation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 1991;65:765–74.

Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. The Journal of Pathology. 2011;223(2):116–126. Available from: https://dx.doi.org/10.1002/path.2784.

Jung MS, Yun J, Hd C. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene. 2001;20:5818–5843.

Gohler T, Jager S, Warnecke G. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res. 2005;33:1087–100.

Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biol. 2007;9(5):573–580. Available from: https://dx.doi.org/10.1038/ncb1571.

Pharoah PDP, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer. 1999;80(12):1968–1973. Available from: https://dx.doi.org/10.1038/sj.bjc.6690628.

Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, et al. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild- type p53 functions. Oncogene. 1999;18(15):2451–2459. Available from: https://dx.doi.org/10.1038/sj.onc.1202565.

Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, et al. Frequency of p53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA1 Mutations. JNCI J National Cancer Inst. 1999;91(5):469–473. Available from: https://dx.doi.org/10.1093/jnci/91.5.469.

Esteller M. Promoter Hypermethylation and BRCA1 Inactiva- tion in Sporadic Breast and Ovarian Tumors. J National Cancer Inst. 2000;92(7):564–569. Available from: https://dx.doi.org/10.1093/jnci/92.7.564.

Malkin D, Li F, Strong L, Fraumeni J, Nelson C, Kim D, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Sci. 1990;250(4985):1233–1238. Available from: https://dx.doi.org/10.1126/science.1978757.

Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunocytochemical analysis of mutant p53 in human breast cancer. Oncogene. 1990;5:893–99.

Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 over expression in human breast cancer. Proceed- ings National Acad Sci. 1991;88(11):5006–5010. Available from: https://dx.doi.org/10.1073/pnas.88.11.5006.

Stankovic T, Kidd AMJ, Sutcliffe A, McGuire GM, Robinson P, Weber P, et al. ATM Mutations and Phenotypes in Ataxia- Telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast Cancer. Am J Human Genetics. 1998;62(2):334–345. Available from: https://dx.doi.org/10.1086/301706.

Angele S, Treilleux I, Taniere P, Martel-Planche G, Villaume M. Abnormal expression of the ATM and TP53 genes in sporadic breast cancer. Clin Cancer Res. 2000;6:3536–3580.

Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. MDM2 gene amplification in human breast cancer. Eur J Cancer. 1994;30(7):982–984. Available from: https://dx.doi.org/10.1016/0959-8049(94)90128-7.

Gentile M, Ahnström M, Schön F, Wingren S. Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis. Oncogene. 2001;20(53):7753–7760. Available from: https://dx.doi.org/10.1038/sj.onc.1204993.

Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al. ASPP Proteins Specifically Stimulate the Apoptotic Function of p53. Molecular Cell. 2001;8(4):781–794. Available from: https://dx.doi.org/10.1016/s1097-2765(01)00367-7.

Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. Nature Genetics. 2000;24(3):300–303. Available from: https://dx.doi.org/10.1038/73536.

Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res Treat. 2001;66:183–90.

Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, et al. p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast. Am J Surg Pathol. 2001;25(8):1054–1060. Available from: https://dx.doi.org/10.1097/00000478-200108000-00010.

Mazars R, Spinardi L, Bencheikh M, Simony-Lafontaine J, Jeanteur P. p53 mutations occur in aggressive breast cancer. Cancer Res. 1992;52:3918–3941.

Pharoah PDP, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer. 1999;80(12):1968–1973. Available from: https://dx.doi.org/10.1038/sj.bjc.6690628.

Norberg T, Klaar S, Karf G, Nordgren H, Holmberg L. Increased p53 mutation frequency during tumor progression - results from a breast cancer cohort. Cancer Res. 2001;61:8317– 8338.

Shao ZM, Wu J, Shen ZZ, Nguyen M. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer. 2001;7:2222–2249.

Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 1996;2(7):811–814. Available from: https://dx.doi.org/10.1038/nm0796-811.

Published
2020-05-27